Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3

Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine kinase that is particularly abundant in the CNS. Dysregulation of GSK-3 activity is believed to play a key role in the pathogenesis of CNS chronic disorders such as Alzheimer's disease (AD), bipolar disorder, and Huntington's disease, and of metabolic disorders such as type II diabetes. Accordingly, GSK-3 inhibitors have been postulated as therapeutic tools for these diseases. Interestingly, pathophysiological and pharmacological regulation of GSK-3 is affected by an amplification mechanism that applies both to inhibition and activation. The possibility therefore exists that sustained inhibition or activation might persist after cessation of the initial trigger. Regarding AD, GSK-3 has been shown to accumulate in pretangle neurons. Furthermore, GSK-3 phosphorylates tau in most serine and threonine residues hyperphosphorylated in PHF (paired helical filament)-tau and GSK-3 activity contributes both to β-amyloid production and to β-amyloid-mediated neuronal death. In good agreement, mice with conditional overexpression of GSK-3 in forebrain neurons (Tet/GSK-3β mice) recapitulate aspects of AD neuropathology such as tau hyperphosphorylation, apoptotic neuronal death, and reactive astrocytosis as well as spatial learning deficit. Here, we exploit the conditional system used to generate Tet/GSK-3β mice to explore whether the biochemical, histopathological, and behavioral consequences of increased GSK-3 activity are susceptible to revert after restoration of normal GSK-3 levels. Here, we show that transgene shutdown in symptomatic mice leads to normal GSK-3 activity, normal phospho-tau levels, diminished neuronal death, and suppression of the cognitive deficit, thus further supporting the potential of GSK-3 inhibitors for AD therapeutics.

[1]  J. Lucas,et al.  Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration , 2006, Neurobiology of Aging.

[2]  M. Hetman,et al.  A Positive Feedback Loop between Glycogen Synthase Kinase 3β and Protein Phosphatase 1 after Stimulation of NR2B NMDA Receptors in Forebrain Neurons* , 2005, Journal of Biological Chemistry.

[3]  J. Lucas,et al.  Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.

[4]  Claire H. Michel,et al.  Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. , 2005, Human molecular genetics.

[5]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[6]  W. Noble,et al.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[8]  Michel Goedert,et al.  GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.

[9]  Jesús Avila,et al.  Glycogen synthase kinase 3: a drug target for CNS therapies , 2004, Journal of neurochemistry.

[10]  Jesus Avila,et al.  Role of tau protein in both physiological and pathological conditions. , 2004, Physiological reviews.

[11]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[12]  F. Liu,et al.  Divergent roles of GSK3 and CDK5 in APP processing. , 2003, Biochemical and biophysical research communications.

[13]  A. Sleight,et al.  Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790 , 2003, Psychopharmacology.

[14]  R. Jope Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. , 2003, Trends in pharmacological sciences.

[15]  C. Phiel,et al.  Inhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium , 2003, Journal of Biological Chemistry.

[16]  Christina A. Wilson,et al.  GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.

[17]  A. Delacourte,et al.  Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology , 2003, Acta Neuropathologica.

[18]  J. Lucas,et al.  Spatial learning deficit in transgenic mice that conditionally over‐express GSK‐3β in the brain but do not form tau filaments , 2002, Journal of neurochemistry.

[19]  D. Rubinsztein,et al.  Glycogen Synthase Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation* , 2002, The Journal of Biological Chemistry.

[20]  A. Takashima,et al.  Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100 , 2002, Neuroscience Letters.

[21]  H. Eldar-Finkelman,et al.  Glycogen synthase kinase 3: an emerging therapeutic target. , 2002, Trends in molecular medicine.

[22]  C. Pérez,et al.  First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. , 2002, Journal of medicinal chemistry.

[23]  R. Belmaker,et al.  GSK-3 and the neurodevelopmental hypothesis of schizophrenia , 2002, European Neuropsychopharmacology.

[24]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[25]  A. Reith,et al.  Selective small‐molecule inhibitors of glycogen synthase kinase‐3 activity protect primary neurones from death , 2001, Journal of neurochemistry.

[26]  A. Reith,et al.  Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. , 2001 .

[27]  René Hen,et al.  Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice , 2001 .

[28]  M. Mercken,et al.  Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic Mice* , 2000, The Journal of Biological Chemistry.

[29]  A. Tobin,et al.  Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.

[30]  C. Granier,et al.  Binding specificity of monoclonal antibody AD2: influence of the phosphorylation state of tau. , 2000, Brain research. Molecular brain research.

[31]  René Hen,et al.  Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.

[32]  H. Braak,et al.  Distribution of Active Glycogen Synthase Kinase 3β (GSK-3β) in Brains Staged for Alzheimer Disease Neurofibrillary Changes , 1999 .

[33]  J. Ávila,et al.  Lithium protects cultured neurons against β‐amyloid‐induced neurodegeneration , 1999 .

[34]  D L Price,et al.  Genetic neurodegenerative diseases: the human illness and transgenic models. , 1998, Science.

[35]  Hans Clevers,et al.  Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis , 1998, Nature.

[36]  I. Grundke‐Iqbal,et al.  τ is phosphorylated by GSK‐3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A‐kinase , 1998, FEBS letters.

[37]  M. Mercken,et al.  Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  K. Kosik,et al.  Selective Phosphorylation of Adult Tau Isoforms in Mature Hippocampal Neurons Exposed to Fibrillar Aβ , 1997, Molecular and Cellular Neuroscience.

[39]  Virginia M. Y. Lee,et al.  Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3* , 1997, The Journal of Biological Chemistry.

[40]  J. Ávila,et al.  Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons , 1997, FEBS letters.

[41]  J. Aggleton,et al.  Spontaneous object recognition and object location memory in rats: the effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the fornix , 1997, Experimental Brain Research.

[42]  J. Ávila,et al.  Glycogen synthase kinase 3 phosphorylation of different residues in the presence of different factors: Analysis on tau protein , 1996, Molecular and Cellular Biochemistry.

[43]  K. Imahori,et al.  Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology , 1996, Brain Research.

[44]  D. Melton,et al.  A molecular mechanism for the effect of lithium on development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Lovestone,et al.  Phosphorylation of tau by glycogen synthase kinase-3β in intact mammalian cells: The effects on the organization and stability of microtubules , 1996, Neuroscience.

[46]  A. Delacourte,et al.  AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. , 1996, Brain research. Molecular brain research.

[47]  K. Imahori,et al.  Exposure of rat hippocampal neurons to amyloid β peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β , 1996, Neuroscience Letters.

[48]  E. Vanmechelen,et al.  Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205 , 1995, Neuroscience Letters.

[49]  B. Yankner,et al.  β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding , 1995, Neuron.

[50]  M. Goedert,et al.  Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404 , 1994, Journal of neuroscience research.

[51]  Simon Lovestone,et al.  Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells , 1994, Current Biology.

[52]  J. Woodgett,et al.  Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. , 1994, The Biochemical journal.

[53]  K. Imahori,et al.  Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Wood,et al.  Functional studies of Alzheimer's disease tau protein , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[55]  E. Mandelkow,et al.  The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region. , 1992, The EMBO journal.

[56]  P. Davies,et al.  Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. , 1992, The Journal of biological chemistry.

[57]  C. Milstein,et al.  Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[59]  G. Lindwall,et al.  Phosphorylation affects the ability of tau protein to promote microtubule assembly. , 1984, The Journal of biological chemistry.

[60]  G. Borisy,et al.  Comparison of the sedimentation properties of microtubule protein oligomers prepared by two different procedures. , 1976, Biochemical and biophysical research communications.

[61]  C. Cantor,et al.  Microtubule assembly in the absence of added nucleotides. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[62]  M. Vandermeeren,et al.  Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes , 2004, Acta Neuropathologica.

[63]  Jesús Avila,et al.  Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. , 2003, Journal of Alzheimer's disease : JAD.

[64]  Christina A. Wilson,et al.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. , 2003, Nature.

[65]  J. Sadoshima,et al.  Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. , 2002, Circulation research.

[66]  J. Woodgett,et al.  Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. , 2002, Advances in cancer research.

[67]  R. Hen,et al.  Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. , 2001, The EMBO journal.

[68]  J. Ávila,et al.  Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. , 1999, FEBS letters.

[69]  H. Braak,et al.  Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. , 1999, Journal of neuropathology and experimental neurology.

[70]  A. Takashima Tau protein I is essential for amyloid β-protein iduced neurotoxicity , 1993 .